Temasek Holdings is considering selling Advanced MedTech, multiple sources told Reuters on Monday, after the medical devices firm, fully-owned by the Singaporean state investor, received interest from suitors including buyout funds.
Two investment banks have been hired to launch a sale process for Singapore-headquartered MedTech, which could be valued at roughly $1 billion, two of the sources said.
All the sources declined to be named as news of the sale process has not been made public.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
A Temasek spokesperson declined comment, while there was no immediate comment from an external spokesperson for Advanced MedTech.
Temasek is a global investment company with a net portfolio value of S$381 billion (US$283b) as at 31 March 2021. Headquartered in Singapore, it has 13 offices in 9 countries around the world.
The Temasek Charter defines Temasek’s three roles as an Investor, Institution and Steward, which shape its ethos to do well, do right, and do good. As a provider of catalytic capital, it seeks to enable solutions to key global challenges.
With sustainability at the core of all Temasek does, it actively seeks sustainable solutions to address present and future challenges, as it captures investible opportunities to bring about a sustainable future for all.
Source: Reuters
Can’t stop reading? Read more
Sixth Street-backed Caris Life Sciences targets $5.35bn valuation in US IPO
Sixth Street-backed Caris Life Sciences targets $5.35bn valuation in US IPO Sixth Street-backed...
Advent eyes $5.06bn Spectris takeover in UK’s biggest buyout bid of 2025
Advent eyes $5.06bn Spectris takeover in UK’s biggest buyout bid of 2025 Advent International has...
CalPERS posts 11.3% private equity return as $92bn strategy revamp gains traction
CalPERS posts 11.3% private equity return as $92bn strategy revamp gains traction The California...